Interferon Treatment in Patients with Hypereosinophilia

Author(s): Ole Weis Bjerrum

Journal Name: Current Drug Targets

Volume 12 , Issue 3 , 2011

Become EABM
Become Reviewer
Call for Editor


Most of the primary conditions with eosinophilia have now been characterized by clonality in 2008 by the WHO classification, which thereby provide a basis for separation of patients who may benefit a targeted therapy, i.e. by tyrosine kinase inhibition - and who may not. Treatment with interferon-α was introduced some 20 years ago and still has a role in subsets of patients, which is evident from this review of casuistic reports of treatment. However, controlled, randomized, prospective, clinical trials in multi-center studies are needed to clarify dosages, monitoring, prognosis and perhaps combination therapies with interferon-α, i.e. antibodies or other immune suppressants, in the rare patients with primary eosinophilia,

Keywords: Eosinophilia, interferon, treatment, classification, review, pure idiopathic hypereosinophilia, hypereosinophilia, cyclophosphamide

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [429 - 432]
Pages: 4
DOI: 10.2174/138945011794815211
Price: $65

Article Metrics

PDF: 7